Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 25 for:    nobelpharma

Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02634931
Recruitment Status : Completed
First Posted : December 18, 2015
Last Update Posted : February 20, 2019
Sponsor:
Information provided by (Responsible Party):
Nobelpharma

Brief Summary:
The purpose of this trial is to evaluate the safety and efficacy of long-term treatment with NPC-12G gel (0.2% sirolimus gel) to angiofibroma and other skin lesions in patients with tuberous sclerosis complex in the open-label trial.

Condition or disease Intervention/treatment Phase
Tuberous Sclerosis Angiofibroma Hypomelanotic Macule Plaque Drug: NPC-12G gel Phase 3

Detailed Description:

Tuberous Sclerosis Complex (TSC) is an autosomal dominant hereditary disease that causes benign tumors on the almost whole body (including skin, brain, kidney, lung and heart), behavior disorder as autism, mental retardation and neurologic symptom as epilepsy. Angiofibroma is a TSC-specific facial skin lesion, and hamartoma caused by increase of the component of skin connective tissues and blood vessels. Other skin lesions due to TSC are white macule (hypomelanotic macule), plaque, shagreen patch and ungual fibromas. Current therapeutic methods for angiofibroma are laser and surgical treatments, but there are problems as many relapses, deficiency of evidence, change of pigment, scar and risk of infection.

This is a multicenter and open-label trial. The trial consists of two phase. In the first trial phase for 52 weeks, the efficacy as well as the safety is evaluated. For the second trial phase the trial will be continued until the date of approval of NDA for NPC-12G. The safety is evaluated during the second trial phase, but not the efficacy. Patients who meet all entry criteria for the trial apply 0.2% NPC-12G gel twice a day. Patients will visit at 4 to 5-week intervals for the first 6 months of the first trial phase, and then 3 months intervals thereafter.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 94 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Long-term, Single-arm, Open-label Trial of NPC-12G (Topical Formulation of Sirolimus) to Angiofibroma and Other Skin Lesions in Patients With Tuberous Sclerosis Complex
Study Start Date : December 2015
Actual Primary Completion Date : October 2018
Actual Study Completion Date : October 2018


Arm Intervention/treatment
Experimental: NPC-12G gel
NPC-12G gel is containing 0.2% Sirolimus
Drug: NPC-12G gel
NPC-12G gel is administered topically twice a day for 52 weeks or longer




Primary Outcome Measures :
  1. The discontinuation rate due to adverse events [ Time Frame: 52 weeks and longer ]
    The first discontinuation in each patient due to adverse events is assessed.Completion of week 26 and 52 are cut-off points for interim-analyses by Kaplan-Meier method


Secondary Outcome Measures :
  1. Adverse events and adverse events related to the test drug [ Time Frame: 52 weeks and longer ]
    The number of discontinuation/ resume due to adverse events are evaluated. Completion of week 26 and 52 are cut-off points for interim-analyses

  2. Adverse events related to the test drug leading to the discontinuation permanently [ Time Frame: 52 weeks and longer ]
    The incidence of adverse events are evaluated. Completion of week 26 and 52 are cut-off points for interim-analyses

  3. Serious adverse events and serious adverse events related to the test drug [ Time Frame: 52 weeks and longer ]
    The incidence of serious adverse events are evaluated. Completion of week 26 and 52 are cut-off points for interim-analyses

  4. Adverse events and adverse events related to the test drug leading to modification of dosage and administration [ Time Frame: 52 weeks and longer ]
    The incidence of adverse events are evaluated. Completion of week 26 and 52 are cut-off points for interim-analyses

  5. Significant adverse events and significant adverse events related to the test drug [ Time Frame: 52 weeks and longer ]
    The incidence of significant adverse events such as local irritation are evaluated. Completion of week 26 and 52 are cut-off points for interim-analyses

  6. Laboratory tests, vital signs [ Time Frame: Baseline and every 3 months for laboratory tests, every scheduled visit for vital sign] ]
    Completion of week 26 and 52 are cut-off points for interim-analyses

  7. Blood level of sirolimus [ Time Frame: Baseline and every 3 months only for the first trial phase ]
    Whole blood level of sirolimus are measured any day time at baseline and every 3 months visit

  8. Improvements in angiofibroma [ Time Frame: Week 4, 8, 12, 26, 39 and 52 ]
    Improvements comparing with baseline is assessed using photograph by the investigator and the central photo-judgement committee. Completion of week 26 is a cut-off point for interim-analysis.

  9. Improvements in sizes of angiofibroma [ Time Frame: Week 4, 8, 12, 26, 39 and 52 ]
    Improvements comparing with baseline is assessed using photograph by the investigator and the central photo-judgement committee. Completion of week 26 is a cut-off point for interim-analysis.

  10. Improvements in redness of angiofibroma [ Time Frame: Week 4, 8, 12, 26, 39 and 52 ]
    Improvements comparing with baseline is assessed using photograph by the investigator and the central photo-judgement committee. Completion of week 26 is a cut-off point for interim-analysis.

  11. Improvements in white macule and plaque upper neck [ Time Frame: Week 4, 8, 12, 26, 39 and 52 ]
    Improvements comparing with baseline is assessed using photograph by the investigator and the central photo-judgement committee. Completion of week 26 is a cut-off point for interim-analysis.

  12. The rate of patients evaluated ''improvement'' or more (improvement rate) in above the efficacy measures. [ Time Frame: Week 4, 8, 12, 26, 39 and 52 ]
    Completion of week 26 is a cut-off point for interim-analysis.

  13. Change in total score of DLQI and CDLQI from baseline [ Time Frame: Week 4, 8, 12, 26, 39 and 52 ]
    DLQI for subjects 16 years old and greater, or CDLQI for children of less than 16 years old is assessed by patients. Completion of week 26 is a cut-off point for interim-analysis.

  14. Degree of patient's satisfaction [ Time Frame: Week 12, 26, 39 and 52 ]
    Patient's satisfaction is assessed by patient. Completion of week 26 is a cut-off point for interim-analysis.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   3 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female patients 3 years old or greater at the time of informed consent
  2. Patients who are diagnosed as definite diagnosis according to diagnostic criteria for tuberous sclerosis complex (International Tuberous Sclerosis Complex Consensus Conference 2012)
  3. Patients with skin lesions such as angiofibroma, white macules or plaque upper neck associated with tuberous sclerosis complex at the screening visit or the baseline visit
  4. Patients or his/her guardian who agree to use the test drug (NPC-12G gel) or who want to participate in the trial again following participation in Phase III trial (NPC-12G-1)
  5. Patient who are considered to be an appropriate patient to participate in the trial by investigator
  6. Patients or his/her guardian who give a written informed consent in understanding and willingness after having received enough explanation of the test drug and the current trial plan

Exclusion Criteria:

  1. Patients who have offered to withdraw from Phase III trial (NPC-12G-1) and have been discontinued
  2. Patients who have not applied the test drug topically more than 25% of whole applications without appropriate reason for Phase III trial (NPC-12G-1)
  3. Patients with clinical findings such as erosion, ulcer and eruption on or around the lesion of angiofibroma, which may affect assessment of safety or efficacy
  4. Patients with a history of hypersensitivity to alcohol or allergy to sirolimus
  5. Patients who have complications such as malignant tumor, infection, serious heart disease, hepatic function disorder, renal function disorder or blood disorders which severity are considered by investigator as grade 2 or more severe with reference to ''Concerning classification criteria for seriousness of adverse drug reactions of medical agents''
  6. Patients who have complications such as diseases unsuitable for the trial participation, for examples, uncontrolled diabetes (fasting blood glucose level >140 mg/dL or postprandial blood glucose level > 200 mg/dL), dyslipidemia (cholesterol level > 300 mg/dL or > 7.75 mmol/L, triglycerides level > 300 mg/dL or > 3.42 mmol/L), etc.
  7. Female patients who may be pregnancy or are lactating
  8. Patients who cannot agree to take appropriate measures of contraception until completion of the trial or follow-up period after discontinuation from informed consent
  9. Patients who have participated in other clinical trial other than Phase III trial (NPC-12G-1) and have taken a trial drug within 6 months before informed consent
  10. Others, patients who are considered by the investigator as unsuitable for participation in the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02634931


Locations
Layout table for location information
Japan
Graduate School of Medicine, Osaka University
Suita, Osaka, Japan, 565-0871
Sponsors and Collaborators
Nobelpharma
Investigators
Layout table for investigator information
Principal Investigator: Mari Wataya-Kaneda,, MD, PhD Department of Dermatology, Graduate School of Medicine, Osaka University

Layout table for additonal information
Responsible Party: Nobelpharma
ClinicalTrials.gov Identifier: NCT02634931     History of Changes
Other Study ID Numbers: NPC-12G-2
First Posted: December 18, 2015    Key Record Dates
Last Update Posted: February 20, 2019
Last Verified: December 2015

Keywords provided by Nobelpharma:
Sirolimus
Skin lesions
TSC
Tuberous Sclerosis Complex
NPC-12G
Angiofibroma
Hypomelanotic Macule
Plaque

Additional relevant MeSH terms:
Layout table for MeSH terms
Sclerosis
Tuberous Sclerosis
Angiofibroma
Pathologic Processes
Hamartoma
Neoplasms
Neoplasms, Multiple Primary
Neoplastic Syndromes, Hereditary
Malformations of Cortical Development, Group I
Malformations of Cortical Development
Nervous System Malformations
Nervous System Diseases
Neurocutaneous Syndromes
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Congenital Abnormalities
Genetic Diseases, Inborn
Neoplasms, Vascular Tissue
Neoplasms by Histologic Type
Sirolimus
Everolimus
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs